Device Trial Radar · NCT06101979
A Prospective Study of Fortiva in Hernia Repair
Last checked: Nov 20, 2026Latest source record: Jul 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
120
Planned (sponsor's estimate)
Start
Nov 15, 2023
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- RTI SurgicalNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 26, 2023
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to evaluate safety and performance of the Fortiva Tissue Matrix. Participants will complete questionnaires to measure outcomes after hernia surgery for two years.
Conditions
- Ventral Hernia
- Incisional Hernia
- Abdominal Wall Reconstruction
Interventions
Fortiva Tissue MatrixDevice
Acellular Dermal Matrix used in hernia surgery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Type of adverse eventsTime frame: 6 weeks, 6 months, 12 months and 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
James Paget University Hospital
Great Yarmouth, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.